DEXEDRINE SPANSULE 15 MG
DEXTROAMPHETAMINE SULFATE : 15 MG · DIN 01924567 · ENDO OPERATIONS LTD.
Health Canada status: MARKETED
What is DEXEDRINE SPANSULE?
DEXEDRINE SPANSULE 15 MG contains DEXTROAMPHETAMINE SULFATE : 15 MG. It is listed in the Health Canada Drug Product Database under DIN 01924567, held by ENDO OPERATIONS LTD., supplied as CAPSULE (SUSTAINED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 25-Feb-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DEXEDRINE SPANSULE used for?
Adjunctive treatment of narcolepsy and treatment of attention deficit hyperactivity disorder (ADHD).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01924567 |
|---|---|
| Brand name | DEXEDRINE SPANSULE |
| Generic / active ingredient | DEXTROAMPHETAMINE SULFATE : 15 MG |
| Manufacturer | ENDO OPERATIONS LTD. |
| Strength | 15 MG |
| Dosage form | CAPSULE (SUSTAINED-RELEASE) |
| Route of administration | ORAL |
| Schedule | CONTROLLED DRUGS (CDSA I) |
| ATC code | N06BA02 DEXAMFETAMINE |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Feb-2026 |
| Original market date | 1991-12-31 00:00:00 |
How is it administered?
Individualize dosage. ADHD/Narcolepsy: 2.5mg to 60mg daily depending on age/indication. Tablets: 1st dose on awakening, then every 4-6 hours. Spansule: once daily. Avoid late evening doses.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refer to section 11 of full monograph).
How is it supplied?
HDPE bottles of 100 tablets (5 mg) or 100 capsules (10 mg, 15 mg).
Contraindications
Hypersensitivity to sympathomimetic amines; advanced arteriosclerosis; symptomatic CV disease; moderate to severe hypertension; hyperthyroidism; glaucoma; agitated states; history of drug abuse.
Warnings and precautions
Potential for abuse, misuse, and dependence. Misuse may cause serious cardiovascular events and sudden death. Stimulants may lower seizure threshold. Monitor growth in children.
What can be used instead?
Other Canadian products sharing ATC code N06BA02 DEXAMFETAMINE. 6 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DEXEDRINE | 5 MG | TABLET | ENDO OPERATIONS LTD. | MARKETED | DIN 01924516 |
| DEXEDRINE SPANSULE | 10 MG | CAPSULE (SUSTAINED-RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 01924559 |
| DEXTROAMPHETAMINE | 5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02443236 |
| TEVA-DEXTROAMPHETAMINE SR | 10 MG | CAPSULE (SUSTAINED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02448319 |
| TEVA-DEXTROAMPHETAMINE SR | 15 MG | CAPSULE (SUSTAINED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02448327 |
| APO-DEXTROAMPHETAMINE SR | 10 MG | CAPSULE (SUSTAINED-RELEASE) | APOTEX INC | APPROVED | DIN 02481464 |
| APO-DEXTROAMPHETAMINE SR | 15 MG | CAPSULE (SUSTAINED-RELEASE) | APOTEX INC | APPROVED | DIN 02481472 |
| PMS-DEXTROAMPHETAMINE | 5 MG | TABLET | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02447673 |
Who else supplies DEXAMFETAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DEXAMFETAMINE appears in 35 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.